Neurocrine Biosciences, Inc. provided earnings guidance for the full year of 2024. For the year, company expects Net Product Sales of $2,100 million to $2,200 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
139.4 USD | -0.79% | -2.03% | +5.80% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.80% | 14.03B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+28.03% | 11.67B | |
-31.18% | 7.55B |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024